Individualised prediction of major bleeding in patients with atrial fibrillation treated with anticoagulation

被引:0
|
作者
Toft-Petersen, Anne Pernille [1 ]
Lee, Christina J. -y. [1 ]
Phelps, Matthew [2 ]
Ozenne, Brice [3 ,4 ]
Gerds, Thomas Alexander [5 ]
Torp-Pedersen, Christian [1 ,2 ,5 ]
机构
[1] Univ Copenhagen, Nordsjaellands Hosp, Dept Cardiol & Clin Res, Hillerod, Denmark
[2] Danish Heart Fdn, Copenhagen, Denmark
[3] Univ Copenhagen, Dept Publ Hlth, Sect Biostat, Copenhagen, Denmark
[4] Copenhagen Univ Hosp, Rigshosp, Neurobiol Res Unit & BrainDrugs, Copenhagen, Denmark
[5] Univ Copenhagen, Dept Biostat, Copenhagen, Denmark
来源
PLOS ONE | 2024年 / 19卷 / 11期
关键词
ORAL ANTICOAGULANTS; RISK SCORES; STROKE; WARFARIN; HEMORRHAGE; THERAPY; REGISTRY; SCHEMES; ORBIT;
D O I
10.1371/journal.pone.0312294
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Anticoagulation in atrial fibrillation (AF) increases the risk of major bleeding. No predictive model has hitherto provided estimates of the absolute risk for individual patients. Aim To predict the individual 1-year risk of major bleeding in patients with AF taking anticoagulants and evaluate the importance of individual risk factors. Design A nationwide register-based cohort study. Participants Danish patients with first-time non-valvular AF who redeemed anticoagulants within 7 days after diagnosis. Method The individual absolute risk of major bleeding was estimated from a logistic regression model (the Calculator of Absolute Bleeding Risk/CABS model) utilising the same risk factors as HAS-BLED, except allowing non-linear age effects, and allowing effect modification of all factors according to history of bleeding. The logistic regression was assessed in term of discrimination using the Area Under the ROC curve (AUC) and calibration. Results Among 76,102 patients with AF redeeming anticoagulants, 2,406 suffered a major bleeding within 1 year. History of bleeding was the strongest predictor, and age significantly modified the risk. The CABS model superseded HAS-BLED score with regards to discrimination (AUC 0.646 vs 0.615, p<0.001) and calibrated well. A typical male patient was 70-years old without any risk factors and he had a 1-year bleeding risk of 1.4% (1.2; 1.6) while a typical female patient was 73-years old, had hypertension and a 1-year bleeding risk of 2.2% (1.9;2.6). Conclusion We propose CABS as a tool for prediction of individual absolute risks of major bleeding in patients with AF taking anticoagulant. The predicted absolute risk can be used for patient counselling.
引用
收藏
页数:14
相关论文
共 50 条
  • [11] Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
    Kirchhof, Paulus
    Haas, Sylvia
    Amarenco, Pierre
    Hess, Susanne
    Lambelet, Marc
    van Eickels, Martin
    Turpie, Alexander G. G.
    Camm, A. John
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (05):
  • [12] Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation
    Hilkens, Nina A.
    Algra, Ale
    Greving, Jacoba P.
    STROKE, 2017, 48 (11) : 3142 - +
  • [13] Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
    Hylek, Elaine M.
    Held, Claes
    Alexander, John H.
    Lopes, Renato D.
    De Caterina, Raffaele
    Wojdyla, Daniel M.
    Huber, Kurt
    Jansky, Petr
    Steg, Philippe Gabriel
    Hanna, Michael
    Thomas, Laine
    Wallentin, Lars
    Granger, Christopher B.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (20) : 2141 - 2147
  • [14] Major bleeding and thromboembolic complications associated with antithrombotic treatment in patients with atrial fibrillation/flutter and incident cancer
    Chu, Gordon
    van Rein, Nienke
    Huisman, Menno, V
    Pedersen, Lars
    Sorensen, Henrik T.
    Cannegieter, Suzanne C.
    Klok, Frederikus A.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2025, 9 (02)
  • [15] Impact of anemia on major bleeding in patients taking oral anticoagulants for nonvalvular atrial fibrillation
    Kinjo, Norito
    Ueda, Shinichiro
    Uchida, Kazutaka
    Sakakibara, Fumihiro
    Nezu, Mari
    Arai, Hideki
    Morimoto, Takeshi
    JOURNAL OF ARRHYTHMIA, 2023, 39 (04) : 556 - 565
  • [16] The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation
    Van den Ham, H. A.
    Klungel, O. H.
    Leufkens, H. G. M.
    Van Staa, T. P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (01) : 107 - 115
  • [17] Ineligibility for Anticoagulation in Patients with Atrial Fibrillation
    del Conde, Ian
    Halperin, Jonathan L.
    AMERICAN JOURNAL OF MEDICINE, 2013, 126 (02) : 105 - 111
  • [18] Underuse of anticoagulation in patients with atrial fibrillation
    Vallakati, Ajay
    Lewis, William R.
    POSTGRADUATE MEDICINE, 2016, 128 (02) : 191 - 200
  • [19] Preventing and Managing Bleeding With Anticoagulation for Atrial Fibrillation
    Granger, Christopher B.
    Pokorney, Sean D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (24) : 3002 - 3004
  • [20] Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation
    Hernandez, Inmaculada
    Zhang, Yuting
    Brooks, Maria M.
    Chin, Paul K. L.
    Saba, Samir
    STROKE, 2017, 48 (01) : 159 - +